The U.S. regenerative medicine market size surpassed USD 14.06 billion in 2025 and is predicted to reach around USD 60.96 bllion by 2035, registering a CAGR of 15.8% from 2026 to 2035. Advancements in stem and cell therapies, along with advanced tissue engineering , are some of the major factors fueling the growth of the market.

U.S. Regenerative Medicine Market Statical Scope

The U.S. regenerative medicine market is also expected to grow due to the growing prevalence of chronic diseases, increased R&D funding, and strong investment in stem cell research. The major inclination of the market towards evidence-based therapies, along with significant investments in stem cell and gene therapy , has helped to fuel the market's growth. The market's growth is also propelled by FDA-approved CAR-T cell therapies and stem cell therapies helpful to treat orthopaedic issues.

U.S. Regenerative Medicine Market, By Product, 2025 (%)

• Therapeutics- The dominating segment of the global market has 45% of market shares along with strong clinical adoptions, robust R&D investments, and increasing usage of regenerative therapies.
• Tools- The segment has a significant share of 25% of the market, as it is critical for research, development, and procedural applications. Technological advancements in the form of 3D organ printing, organoids, tissue engineering, and AI-enabled research tools.
• Banks- The segment holds 20% market share, and it is also essential for biobanking and storage of stem cells and tissues. The segment's growth is also aided by private cord blood banking, stem cell research, and advanced storage techniques.
• Services- The segment has 10% of market hold, and it also covers factors such as consulting, processing, and support services.

The U.S. Regenerative Medicine Market, By Therapeutic Category, 2025 (%)

• Dermatology- The dominating segment has 30% of the market share due to higher demand for skin rejuvenation devices , wound healing, and aesthetic procedures.
• Musculoskeletal- The segment has a significant share of 25% due to its higher usage in orthopaedic treatments and injury repair.
• Immunology and Inflammation- The segment has a hold of 20% of market share and is driven by a major focus on immune-related and inflammatory conditions.
• Oncology- The segment has 13% of the market share, mainly due to its rising application for cancer treatment.

Top Companies in the U.S. Regenerative Medicine Market

• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• Integra Lifesciences Corp.
• Astellas Pharma, Inc.
• Cook Biotech, Inc.
• Bayer AG
• Pfizer, Inc.
• Merck KGaA
• Abbott
• Vericel Corp.
• Novartis AG
• GlaxoSmithKline (GSK)

Segments Covered in the Report

By Product

• Therapeutics
  • Primary cell-based therapeutics
    • Dermatology
    • Musculoskeletal
    • Surgical
    • Dental
    • Others
  • Stem Cell & Progenitor Cell-based therapeutics
    • Autologous
    • Allogenic
    • Others
  • Cell-based Immunotherapies
  • Gene Therapies
• Tools
• Banks
• Services

By Therapeutic Category

• Dermatology
• Musculoskeletal
• Immunology & Inflammation
• Oncology
• Cardiovascular
• Ophthalmology
• Others